AMAZON.COM, INC. et al. v. Nokia Technologies Oy

Amazon.com, Inc. et al.vsDatonics LLC

Amazon and Datonics have settled their IPR dispute over U.S. Patent 10,984,445 and jointly request the Board to terminate the proceeding while keeping the settlement agreement confidential.

Fujirebio Diagnostics, Inc.vsQuanterix Corp.

Fujirebio Diagnostics petitions to invalidate Quanterix’s 2022 patent on tau‑protein blood assays, asserting that the method is obvious over existing single‑molecule array publications and an earlier tau‑diagnostic patent. The petition requests the PTAB to institute an IPR and cancel the challenged claims.

Dr. Falk Pharma GmbHvsEllodi Pharmaceuticals

Dr. Falk Pharma challenges Ellodi's U.S. Patent 12,290,598 covering orally disintegrating tablets, asserting lack of written description, enablement, indefiniteness, anticipation, and obviousness over numerous prior‑art references. The petition seeks cancellation of all 34 claims.

POSCO Co., Ltd. et al.vsARCELORMITTAL

ArcelorMittal seeks Director Review of the PTAB’s decision to institute an IPR covering claims 1‑30 of its high‑strength aluminum alloy‑coated steel patent. The owner contends the Board abused its discretion by misapplying Fintiv factors, particularly Factor One and Factor Four, in violation of §314(a).

Microsoft Corp.vsVirtaMove, Corp.

Microsoft and VirtaMove jointly filed a motion asking the PTAB to keep their settlement agreement confidential under 35 U.S.C. §317(b), citing the sensitivity of the information.